The Journal of Immunology, Vol 154, Issue 9 4576-4582, Copyright © 1995 by American Association of Immunologists

ARTICLES

Retargeting of CTL by an efficiently refolded bispecific single-chain Fv dimer produced in bacteria

I Kurucz, JA Titus, CR Jost, CM Jacobus and DM Segal
Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

A single-chain bispecific Fv dimer (bs(sFv)2) having specificity for mouse CD3 epsilon chain and human transferrin receptor was produced in bacterial inclusion bodies. To overcome difficulties associated with in vitro protein folding, we used a novel renaturation approach to obtain active bs(sFv)2. The protein was dissolved in the weak ionic detergent sodium lauroylsarcosine, and disulfides were formed by oxidation in air. After oxidation, the bs(sFv)2 exhibited very little covalent aggregation and migrated as a single species in nonreducing SDS-PAGE, suggesting that disulfides were correctly paired. The detergent was removed using an ion exchange resin and the protein fractionated by size exclusion chromatography. The recovered 65-kDa protein was monomeric in non-denaturing solvent, homogeneous by SDS-PAGE, and comprised 15 to 20% of material applied to the gel filtration column. This protein bound specifically to both mouse CD3 epsilon chain and human transferrin receptor with affinities indistinguishable from those of the parental Fabs or single-chain Fvs. The bs(sFv)2 specifically redirected mouse cytotoxic T cells to lyse target cells expressing human transferrin receptor at picomolar concentrations. Bacterially produced and detergent oxidized bs(sFv)2 molecules may therefore provide the abundant amounts of homogeneous active material required to redirect cytotoxic cells against tumors and other unwanted cells in animal models and in patients.

This article has been cited by other articles:

				L. Grosse-Hovest, S. Muller, R. Minoia, E. Wolf, V. Zakhartchenko, H. Wenigerkind, C. Lassnig, U. Besenfelder, M. Muller, S. D. Lytton, et al. Cloned transgenic farm animals produce a bispecific antibody for T cell-mediated tumor cell killing PNAS, May 4, 2004; 101(18): 6858 - 6863. [Abstract] [Full Text] [PDF]

				H. Bruhl, J. Cihak, M. Stangassinger, D. Schlondorff, and M. Mack Depletion of CCR5-Expressing Cells with Bispecific Antibodies and Chemokine Toxins: A New Strategy in the Treatment of Chronic Inflammatory Diseases and HIV J. Immunol., February 15, 2001; 166(4): 2420 - 2426. [Abstract] [Full Text] [PDF]

				A. Schmiedl, F. Breitling, and S. Dubel Expression of a bispecific dsFv-dsFv' antibody fragment in Escherichia coli Protein Eng. Des. Sel., October 1, 2000; 13(10): 725 - 734. [Abstract] [Full Text] [PDF]

				B. Cochlovius, S. M. Kipriyanov, M. J. J. G. Stassar, O. Christ, J. Schuhmacher, G. Strau{beta}, G. Moldenhauer, and M. Little Treatment of Human B Cell Lymphoma Xenografts with a CD3 CD19 Diabody and T Cells J. Immunol., July 15, 2000; 165(2): 888 - 895. [Abstract] [Full Text] [PDF]

				J. De Jonge, C. Heirman, M. d. Veerman, S. Van Meirvenne, M. Moser, O. Leo, and K. Thielemans In Vivo Retargeting of T Cell Effector Function by Recombinant Bispecific Single Chain Fv (Anti-CD3 Anti-Idiotype) Induces Long-Term Survival in the Murine BCL1 Lymphoma Model J. Immunol., August 1, 1998; 161(3): 1454 - 1461. [Abstract] [Full Text] [PDF]

				J. de Kruif and T. Logtenberg Leucine Zipper Dimerized Bivalent and Bispecific scFv Antibodies from a Semi-synthetic Antibody Phage Display Library J. Biol. Chem., March 29, 1996; 271(13): 7630 - 7634. [Abstract] [Full Text] [PDF]